JP2020505017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505017A5 JP2020505017A5 JP2019536981A JP2019536981A JP2020505017A5 JP 2020505017 A5 JP2020505017 A5 JP 2020505017A5 JP 2019536981 A JP2019536981 A JP 2019536981A JP 2019536981 A JP2019536981 A JP 2019536981A JP 2020505017 A5 JP2020505017 A5 JP 2020505017A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- represented
- monoclonal antibody
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 239000013604 expression vector Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710054783.5 | 2017-01-24 | ||
| CN201710054783.5A CN108341871A (zh) | 2017-01-24 | 2017-01-24 | 抗pd-1单克隆抗体及其制备方法和应用 |
| PCT/CN2018/073575 WO2018137576A1 (zh) | 2017-01-24 | 2018-01-22 | 抗pd-1单克隆抗体及其制备方法和应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505017A JP2020505017A (ja) | 2020-02-20 |
| JP2020505017A5 true JP2020505017A5 (enExample) | 2020-11-19 |
| JP7098629B2 JP7098629B2 (ja) | 2022-07-11 |
Family
ID=62962821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536981A Active JP7098629B2 (ja) | 2017-01-24 | 2018-01-22 | 抗ｐｄ－１モノクローナル抗体、その製造方法及び用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11254746B2 (enExample) |
| EP (1) | EP3575322B1 (enExample) |
| JP (1) | JP7098629B2 (enExample) |
| CN (2) | CN108341871A (enExample) |
| WO (1) | WO2018137576A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111196855B (zh) * | 2018-11-19 | 2022-11-15 | 三生国健药业（上海）股份有限公司 | 抗egfr/pd-1双特异性抗体 |
| CN111196856A (zh) | 2018-11-19 | 2020-05-26 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体 |
| CN111518206B (zh) * | 2019-02-01 | 2022-03-29 | 长春金赛药业有限责任公司 | 人源化抗Aβ单克隆抗体及其应用 |
| CN109748965A (zh) * | 2019-03-13 | 2019-05-14 | 安徽安科生物工程（集团）股份有限公司 | 全人源pd-l1单克隆抗体及其制备方法和应用 |
| CN109929037B (zh) * | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | 针对程序性死亡配体的结合物及其应用 |
| CN110563849B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
| CN115038718B (zh) * | 2019-11-08 | 2024-07-02 | 山东先声生物制药有限公司 | 抗人程序性死亡配体-1（pd-l1）的抗体及其用途 |
| CN113563473A (zh) | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| CA3181776A1 (en) * | 2020-05-26 | 2021-12-02 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antibodies |
| CN113754767A (zh) * | 2020-06-03 | 2021-12-07 | 上海恒润达生生物科技股份有限公司 | 抗人pd-1抗体及其用途 |
| CN111647624A (zh) * | 2020-06-10 | 2020-09-11 | 成都和同易创生物科技有限公司 | Tsab人源单克隆抗体重组载体、重组抗体及其制备方法 |
| CN113797330A (zh) * | 2020-06-11 | 2021-12-17 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1单克隆抗体液体制剂 |
| CN114761434B (zh) * | 2020-09-30 | 2023-06-27 | 苏州沙砾生物科技有限公司 | Pd-1抗体及其制备方法与应用 |
| US20250270320A1 (en) * | 2020-12-10 | 2025-08-28 | Eutilex Co., Ltd. | Anti-pd-1 antibody and uses thereof |
| CN114316047B (zh) * | 2021-01-14 | 2023-12-22 | 东大生物技术(苏州)有限公司 | 一组pd-1单克隆抗体及其医药用途 |
| CN113980129B (zh) * | 2021-01-15 | 2023-07-28 | 东大生物技术(苏州)有限公司 | 一组il-11单克隆抗体及其医药用途 |
| CN113150154B (zh) * | 2021-04-15 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 抗人pdl1单克隆抗体及其用途 |
| CN115536749A (zh) * | 2021-06-29 | 2022-12-30 | 三生国健药业（上海）股份有限公司 | 三特异性抗体、其制备方法和用途 |
| CN114539407B (zh) * | 2021-12-31 | 2023-04-18 | 浙江大学 | 一种全人源抗PD-1的单克隆抗体No.1-10及其应用 |
| CN114539406B (zh) * | 2021-12-31 | 2023-04-14 | 浙江大学 | 一种全人源抗PD-1的单克隆抗体No.8-3及其应用 |
| EP4532556A4 (en) * | 2022-06-01 | 2026-06-17 | Syncromune Inc | CANCER TREATMENT METHOD BY LYSIS OF TUMOR CELLS AND INTRATUMORAL ADMINISTRATION OF COMBINATIONS OF IMMUNOTHERAPEUTIC INGREDIENTS |
| CN115925947B (zh) * | 2022-09-27 | 2023-08-22 | 上海百英生物科技股份有限公司 | 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟 |
| CN115951055B (zh) * | 2022-12-13 | 2024-10-15 | 湖南湘医投蕙尧生命科技有限公司 | 一种癌症相关蛋白及其抗体和应用 |
| WO2025128263A1 (en) * | 2023-12-15 | 2025-06-19 | Pharmaessentia Corporation | Anti-pd-1 monoclonal antibody and methods of preparation thereof |
| CN120078772A (zh) * | 2025-03-11 | 2025-06-03 | 上海交通大学医学院附属仁济医院 | A61603作为抗肝癌治疗药物的应用 |
| CN120518767B (zh) * | 2025-05-30 | 2025-11-11 | 中国人民解放军军事科学院军事医学研究院 | 一种pd-1单克隆抗体及其应用 |
| CN121021692A (zh) * | 2025-06-23 | 2025-11-28 | 上海百英生物科技股份有限公司 | 一种具有阻断活性的抗人pd-1单克隆抗体或其抗原结合片段及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) * | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| AU2009290544B2 (en) * | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| WO2013169693A1 (en) * | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| CA3175360C (en) * | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104250302B (zh) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| UA122479C2 (uk) * | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| KR102524920B1 (ko) | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | 항-pd-1 항체 |
| CN105330740B (zh) * | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| CN105622753B (zh) * | 2014-11-04 | 2019-04-09 | 博生吉医药科技(苏州)有限公司 | 一种pd-1单克隆抗体及其应用 |
| CN105061597B (zh) * | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| CN106336460B (zh) | 2015-07-15 | 2021-02-12 | 杭州贝颐药业有限公司 | 抗人pd-1蛋白抗体及其编码基因和应用 |
| PE20231958A1 (es) * | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| RU2722451C1 (ru) | 2015-09-29 | 2020-06-01 | Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. | Pd-1 антитела и их применение. |
| CN106008714B (zh) | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
-
2017
- 2017-01-24 CN CN201710054783.5A patent/CN108341871A/zh active Pending
-
2018
- 2018-01-22 WO PCT/CN2018/073575 patent/WO2018137576A1/zh not_active Ceased
- 2018-01-22 CN CN201880007287.7A patent/CN110225928B/zh active Active
- 2018-01-22 JP JP2019536981A patent/JP7098629B2/ja active Active
- 2018-01-22 US US16/480,014 patent/US11254746B2/en active Active
- 2018-01-22 EP EP18745412.9A patent/EP3575322B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106604932B (zh) | 人白细胞介素-2的免疫刺激单克隆抗体 | |
| CN106883297B (zh) | 基于ch3结构域的异二聚体分子、其制备方法及用途 | |
| JP2024026132A5 (enExample) | ||
| TW201815825A (zh) | 經修飾之抗原結合fab片段及包含其之抗原結合分子 | |
| JP2011505810A5 (enExample) | ||
| JP2017114866A5 (enExample) | ||
| WO2016110267A1 (zh) | 具有共同轻链的双特异性抗体或抗体混合物 | |
| JP2025067915A5 (enExample) | ||
| FI3390451T3 (fi) | Kaninisoidut ihmisen vasta-aineet ihmisen ja koiraeläimen il-4r alfaa kohtaan | |
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| CN118359719B (zh) | 人抗人pla2r抗体标准品及其应用 | |
| TW202222824A (zh) | Egfr結合複合物及其製備和使用方法 | |
| JP2024516098A5 (enExample) | ||
| CN117551200A (zh) | 一种抗人cd45抗体或其抗原结合片段及其制备方法 | |
| CN113912728B (zh) | 降低抗人白介素-33单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法 | |
| CN105399830B (zh) | 抗egfr人源化单克隆抗体、其制备方法及用途 | |
| JP7321159B2 (ja) | 薬剤生成物不純物を特性決定するためのシステム及び方法 | |
| JP2026004435A5 (enExample) | ||
| CN112521493B (zh) | 抗口蹄疫o型病毒单克隆抗体及其应用 | |
| CN104341501B (zh) | 抗IL-1β人源化单克隆抗体及其制备方法和应用 | |
| RU2013139743A (ru) | Гуманизированное моноклональное антитело, специфичное к синдекану-1 | |
| JP2022102539A (ja) | 抗体の抗原に対する親和性を向上させる方法及びその利用 | |
| US20240228595A1 (en) | Methods for Monoclonal Antibody Generation | |
| KR20230124280A (ko) | 메르스 코로나 바이러스의 뉴클레오캡시드 단백질에 특이적인 진단용 항체 및 이의 용도 | |
| CN116547303A (zh) | Egfr结合复合物及其制备和使用方法 |